Inventor · disambiguated record
Daniel J. Wendt
Also filed as: WENDT DANIEL · WENDT DANIEL J
23 granted patents·10 pending applications·616 citations·filing 1992–2025
96Inventor score
Top patents by PatentIndex Score
33 records- 0197US7534595B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2007·Granted May 19, 2009·79 cites·34 claims
- 0296US7537923B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted May 26, 2009·49 cites·9 claims
- 0394US9834587B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·6 cites·12 claims
- 0494US9834588B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·7 cites·12 claims
- 0594US8198242B2Variants of C-type natriuretic peptideWENDT DANIEL J·Filed 2010·Granted Jun 12, 2012·46 cites·17 claims
- 0694US7790433B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2009·Granted Sep 7, 2010·32 cites·6 claims
- 0793US10301369B2Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteinsBIOMARIN PHARM INC·Filed 2017·Granted May 28, 2019·5 cites·17 claims
- 0892US10646550B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2018·Granted May 12, 2020·7 cites·13 claims
- 0992US9771408B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Sep 26, 2017·4 cites·12 claims
- 1092US5324649AEnzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereofGENENCOR INT·Filed 1992·Granted Jun 28, 1994·318 cites·38 claims
- 1191US9845346B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 19, 2017·4 cites·12 claims
- 1291US9376480B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2013·Granted Jun 28, 2016·6 cites·21 claims
- 1390US11254725B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2019·Granted Feb 22, 2022·2 cites·13 claims
- 1490US8598121B2Variants of C-type natriuretic peptideWENDT DANIEL J·Filed 2012·Granted Dec 3, 2013·15 cites·14 claims
- 1590US8377884B2Variants of C-type natriuretic peptidesBIOMARIN PHARM INC·Filed 2008·Granted Feb 19, 2013·27 cites·24 claims
- 1688USRE48267EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2017·Granted Oct 20, 2020·2 cites·76 claims
- 1786US2024374688A1Use of C-Type Natriuretic Peptide Variants to Treat Skeletal DysplasiaBIOMARIN PHARM INC·Filed 2024·Application pending·0 cites
- 1882US12076372B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2023·Granted Sep 3, 2024·0 cites·16 claims
- 1981US9907834B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2016·Granted Mar 6, 2018·3 cites·8 claims
- 2080US11505790B2Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2019·Granted Nov 22, 2022·1 cites·14 claims
- 2180US10221408B2Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2016·Granted Mar 5, 2019·3 cites·18 claims
- 2280US2022127326A1Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses ThereofBIOMARIN PHARM INC·Filed 2022·Application pending·0 cites
- 2377US2025388644A1Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2025·Application pending·0 cites
- 2476US2024035013A1Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2022·Application pending·0 cites
- 2569US11911446B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2020·Granted Feb 27, 2024·0 cites·27 claims
- 2669US11590204B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 2760US2024318156A1Compositions of beta-hexosaminidase variants and uses thereofBIOMARIN PHARM INC·Filed 2022·Application pending·0 cites
- 2859US2017051033A1Variants of C-Type Natriuretic PeptideBIOMARIN PHARM INC·Filed 2016·Application pending·0 cites
- 2956USRE46707EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2015·Granted Feb 13, 2018·0 cites·17 claims
- 3054US2016256553A1Variants of C-Type Natriuretic PeptideBIOMARIN PHARM INC·Filed 2015·Application pending·0 cites
- 3152US2010278802A1Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2010·Application pending·0 cites
- 3251US2013039898A1Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2011·Application pending·0 cites
- 3349US2023192799A1CNP Variants and Conjugates ThereofBIOMARIN PHARM INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel J. Wendt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →